Literature DB >> 16133416

Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test.

F A Haddad1, K Van Horn, C Carbonaro, M Aguero-Rosenfeld, G P Wormser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16133416     DOI： 10.1007/s10096-005-1366-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  13 in total

1.  In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.

Authors:  Felipe Fernández-Cuenca; Luis Martínez-Martínez; Alvaro Pascual; Evelio J Perea
Journal:  Chemotherapy       Date:  2003-05       Impact factor: 2.544

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.

Authors:  M J Rodríguez-Hernández; J Pachón; C Pichardo; L Cuberos; J Ibáñez-Martínez; A García-Curiel; F J Caballero; I Moreno; M E Jiménez-Mejías
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii.

Authors:  E J Giamarellos-Bourboulis; E Xirouchaki; H Giamarellou
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

6.  Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.

Authors:  V M Manikal; D Landman; G Saurina; E Oydna; H Lal; J Quale
Journal:  Clin Infect Dis       Date:  2000-07-17       Impact factor: 9.079

7.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

Review 8.  Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment.

Authors:  J M Cisneros; J Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2002-11       Impact factor: 8.067

9.  Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.

Authors:  David Landman; John M Quale; David Mayorga; Adedeyo Adedeji; Kalyani Vangala; Jayshree Ravishankar; Carlos Flores; Steven Brooks
Journal:  Arch Intern Med       Date:  2002-07-08

10.  Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis.

Authors:  O Lortholary; J Y Fagon; A B Hoi; M A Slama; J Pierre; P Giral; R Rosenzweig; L Gutmann; M Safar; J Acar
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079
View more
  6 in total

Review 1.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

Authors:  A Batirel; I I Balkan; O Karabay; C Agalar; S Akalin; O Alici; E Alp; F A Altay; N Altin; F Arslan; T Aslan; N Bekiroglu; S Cesur; A D Celik; M Dogan; B Durdu; F Duygu; A Engin; D O Engin; I Gonen; E Guclu; T Guven; C A Hatipoglu; S Hosoglu; M K Karahocagil; A U Kilic; B Ormen; D Ozdemir; S Ozer; N Oztoprak; N Sezak; V Turhan; N Turker; H Yilmaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-15       Impact factor: 3.267

3.  Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.

Authors:  Fatih Temocin; Fatma Sebnem Erdinc; Necla Tulek; Meryem Demirelli; Gunay Ertem; Sami Kinikli; Eda Koksal
Journal:  Braz J Microbiol       Date:  2015 Oct-Dec       Impact factor: 2.476

4.  Molecular mechanisms related to colistin resistance in Enterobacteriaceae.

Authors:  Zahra Aghapour; Pourya Gholizadeh; Khudaverdi Ganbarov; Abed Zahedi Bialvaei; Suhad Saad Mahmood; Asghar Tanomand; Mehdi Yousefi; Mohammad Asgharzadeh; Bahman Yousefi; Hossein Samadi Kafil
Journal:  Infect Drug Resist       Date:  2019-04-24       Impact factor: 4.003

5.  Control and Elimination of Extensively Drug-Resistant Acinetobacter baumanii in an Intensive Care Unit.

Authors:  Amanda Chamieh; Tania Dagher Nawfal; Tala Ballouz; Claude Afif; George Juvelekian; Sani Hlais; Jean-Marc Rolain; Eid Azar
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

6.  Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Authors:  Ryan K Shields; Cornelius J Clancy; Louise M Gillis; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Gregory A Eschenauer; Brian A Potoski; M Hong Nguyen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.